Naltrexone Patent Expiration
Naltrexone is Used for treating alcohol dependence. It was first introduced by Alkermes Inc
Naltrexone Patents
Given below is the list of patents protecting Naltrexone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vivitrol | US7919499 | Naltrexone long acting formulations and methods of use | Oct 15, 2029 | Alkermes |
| Vivitrol | US6495164 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Alkermes |
| Vivitrol | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Alkermes |
| Vivitrol | US7799345 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Alkermes |
| Vivitrol | US6264987 | Method for preparing microparticles having a selected polymer molecular weight |
May 19, 2020
(Expired) | Alkermes |
| Vivitrol | US6379704 | Method for preparing microparticles having a selected polymer molecular weight |
May 19, 2020
(Expired) | Alkermes |
| Vivitrol | US6534092 | Method for preparing microparticles having a selected polymer molecular weight |
May 19, 2020
(Expired) | Alkermes |
| Vivitrol | US6331317 | Apparatus and method for preparing microparticles |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6395304 | Apparatus and method for preparing microparticles |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6495166 | Apparatus and method for preparing microparticles using in-line solvent extraction |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6537586 | Apparatus and method for preparing microparticles |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6713090 | Apparatus and method for preparing microparticles |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6939033 | Method and apparatus for preparing microparticles using in-line solvent extraction |
Nov 12, 2019
(Expired) | Alkermes |
| Vivitrol | US6194006 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Alkermes |
| Vivitrol | US6379703 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Alkermes |
| Vivitrol | US6596316 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Alkermes |
| Vivitrol | US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Alkermes |
| Vivitrol | US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Alkermes |
| Vivitrol | US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Alkermes |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Naltrexone's patents.
Latest Legal Activities on Naltrexone's Patents
Given below is the list recent legal activities going on the following patents of Naltrexone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Oct, 2022 | US7919499 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Mar, 2022 | US7799345 |
| Termination or Final Written Decision | 31 Jul, 2019 | US7919499 |
| Request for Trial Granted Critical | 07 Nov, 2018 | US7919499 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2018 | US7919499 |
| Petition Requesting Trial | 20 Apr, 2018 | US7919499 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2018 | US7799345 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Apr, 2011 | US7919499 |
| Recordation of Patent Grant Mailed Critical | 05 Apr, 2011 | US7919499 |
| Email Notification Critical | 17 Mar, 2011 | US7919499 |
Naltrexone's Family Patents
Explore Our Curated Drug Screens
Naltrexone Generic API Manufacturers
Only one generic application has been filed for Naltrexone.
Given below is the list of companies who have filed for Naltrexone generic, along with the locations of their manufacturing plants worldwide.
1. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Naltrexone. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 380MG/VIAL | for suspension, extended release | Discontinued | INTRAMUSCULAR | N/A | Jul 6, 2023 |